Anika Therapeutics Inc. (ANIK) CEO Sells $359,699.64 in Stock
Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Charles H. Sherwood sold 5,991 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $60.04, for a total value of $359,699.64. Following the completion of the sale, the chief executive officer now owns 158,297 shares of the company’s stock, valued at $9,504,151.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Anika Therapeutics Inc. (ANIK) traded down 0.53% during midday trading on Tuesday, hitting $59.59. The company’s stock had a trading volume of 55,651 shares. The firm has a 50-day moving average of $57.72 and a 200 day moving average of $50.52. The firm has a market cap of $873.47 million, a price-to-earnings ratio of 26.47 and a beta of 1.66. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $60.29.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The business had revenue of $33.50 million during the quarter, compared to analysts’ expectations of $27.20 million. During the same period in the previous year, the firm posted $0.57 earnings per share. The company’s revenue was up 25.9% on a year-over-year basis. On average, equities research analysts predict that Anika Therapeutics Inc. will post $2.20 EPS for the current fiscal year.
WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/anika-therapeutics-inc-anik-ceo-sells-359699-64-in-stock.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue grew its stake in shares of Anika Therapeutics by 79.5% in the second quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,272 shares in the last quarter. Mason Street Advisors LLC grew its stake in shares of Anika Therapeutics by 7.1% in the first quarter. Mason Street Advisors LLC now owns 3,423 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 228 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Anika Therapeutics by 68.4% in the first quarter. Victory Capital Management Inc. now owns 3,452 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,402 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in shares of Anika Therapeutics by 3.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 100 shares in the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Anika Therapeutics in the first quarter valued at $204,000. 84.44% of the stock is owned by institutional investors and hedge funds.
Several brokerages have weighed in on ANIK. Zacks Investment Research upgraded Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.